Angiogenesis is a prerequisite for breast cancer growth, invasion, and metastasis.[5] Bevacizumab is an anti-angiogenic monoclonal antibody against vascular endothelial growth factor (VEGF) A, which suppresses tumor growth by inhibiting neoangiogenesis. Here, VEGFA is linked to breast cancer.